株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

製薬業の提携・ライセンス・投資・M&A取引と動向

Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals

発行 GlobalData 商品コード 331738
出版日 ページ情報 英文 138 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.14円で換算しております。
Back to Top
製薬業の提携・ライセンス・投資・M&A取引と動向 Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals
出版日: 2017年06月01日 ページ情報: 英文 138 Pages
概要

当レポートでは、世界の製薬業の提携・ライセンス・M&A・資金調達に関する主要データと動向分析に焦点を当てて、過去5年間の取引件数と取引額 (取引タイプ・治療分野・地域別) について検証し、製薬業の投資顧問会社に関する情報も含めて、体系的な情報を提供しています。

第1章 目次

第2章 世界の製薬・医療市場:取引サマリー

  • 取引分析
  • タイプ別、取引件数
  • タイプ別、取引額
  • 主要取引
  • 主要取引サマリー

第3章 世界の製薬・医療市場:主要取引契約者

第4章 世界の製薬・医療市場:取引サマリー (タイプ別)

  • M&A
  • 株式発行取引
  • 債券発行取引
  • 提携取引
  • ライセンス契約
  • 未公開株式発行取引
  • ベンチャーキャピタル取引

第5章 世界の製薬・医療市場:取引サマリー (市場別)

  • 腫瘍
  • 中枢神経系
  • 感染症
  • 免疫系
  • 心血管系
  • 代謝障害
  • 消化管

第6章 製薬・医療市場:取引サマリー (地域別)

  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第7章 世界の製薬・医療市場:主要投資顧問会社

  • M&A
  • 株式発行

第8章 その他の情報

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends for 2016 in Pharmaceuticals" report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in 2016. The report portrays detailed comparative data on the number of deals and their value in the last five years, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalData's proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena.
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women's health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the five years.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include - North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 6
  • 1.2 List of Figures 9

2 Pharmaceutical & Healthcare, Global, Deals Summary 13

  • 2.1 Pharmaceutical & Healthcare, Global, Deals Analysis, 2016 13
    • 2.1.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, 2016 by Quarter 14
  • 2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, 2016 16
  • 2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, 2016 17
  • 2.4 Pharmaceuticals & Healthcare, Global, Top Deals, 2016 18
  • 2.5 Pharmaceuticals & Healthcare, Top Deals, Global, Summaries, 2016 18
    • 2.5.1 Bayer to Acquire Monsanto for USD66 Billion 18
    • 2.5.2 Shire Acquires Baxalta for USD32 Billion 19
    • 2.5.3 Abbott Labs Prices Public Offering of Notes for USD15.1 Billion 20
    • 2.5.4 Teva Pharma Raises USD15 Billion in Public Offering of Notes 20
    • 2.5.5 Pfizer Acquires Medivation in Tender Offer 20
    • 2.5.6 Shire Raises USD12.1 Billion in Public Offering of Notes 21
    • 2.5.7 Mylan Acquires Meda for USD9.9 Billion 22
    • 2.5.8 AbbVie Acquires Stemcentrx 22
    • 2.5.9 AbbVie to Raise USD7.8 Billion in Public Offering of Notes 23
    • 2.5.10 Pfizer Raises USD6 Billion in Public Offering of Notes 23

3 Pharmaceuticals & Healthcare, Global, Top Deal Makers, 2016 24

4 Pharmaceuticals & Healthcare, Global, Deal Summary, by Type 25

  • 4.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 25
    • 4.1.1 Pharmaceuticals & Healthcare, Global, M&A, 2016 by Quarter 26
    • 4.1.2 Top M&A Deals in 2016 27
    • 4.1.3 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, 2016 28
  • 4.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 29
    • 4.2.1 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, 2016 by Quarter 30
    • 4.2.2 Pharmaceuticals & Healthcare, Global, IPO Deals, 2016 31
    • 4.2.3 Top IPOs in 2016 32
    • 4.2.4 Pharmaceuticals & Healthcare, Global, Secondary Offerings Deals, 2016 32
    • 4.2.5 Top Secondary Offerings in 2016 33
    • 4.2.6 Pharmaceuticals & Healthcare, Global, PIPE Deals, 2016 34
    • 4.2.7 Top PIPE Deals in 2016 35
    • 4.2.8 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, 2016 35
  • 4.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, 2016 36
    • 4.3.1 Pharmaceuticals & Healthcare, Global Debt Offerings, 2016 by Quarter 37
    • 4.3.2 Pharmaceuticals & Healthcare, Global, Public Debt Offerings, 2016 38
    • 4.3.3 Top Public Debt Offerings in 2016 39
    • 4.3.4 Pharmaceuticals & Healthcare, Global, Private Debt Placements, 2016 40
    • 4.3.5 Top Private Debt Placements in 2016 41
    • 4.3.6 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, 2016 41
  • 4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 42
    • 4.4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, 2016 by Quarter 43
    • 4.4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, 2016 45
    • 4.4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 46
    • 4.4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 47
    • 4.4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, 2016 48
    • 4.4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), 2016 48
    • 4.4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 50
    • 4.4.8 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, 2016 51
    • 4.4.9 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2016 52
    • 4.4.10 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2016 52
  • 4.5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 53
    • 4.5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, 2016 by Quarter 54
    • 4.5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, 2016 55
    • 4.5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Value (US$ m), 2016 56
    • 4.5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 57
    • 4.5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 58
    • 4.5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), 2016 59
    • 4.5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 61
    • 4.5.8 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Values, 2016 62
    • 4.5.9 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2016 63
    • 4.5.10 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2016 63
  • 4.6 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 64
    • 4.6.1 Pharmaceuticals & Healthcare, Global, Private Equity Deals, 2016 by Quarter 65
    • 4.6.2 Top Private Equity Deals in 2016 66
    • 4.6.3 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, 2016 66
  • 4.7 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, 2016 68
    • 4.7.1 Pharmaceuticals & Healthcare, Global, Venture Financing Deals, 2016 by Quarter 69
    • 4.7.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70
    • 4.7.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, 2016 70
    • 4.7.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, 2016 71
    • 4.7.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 72
    • 4.7.6 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, 2016 73
    • 4.7.7 Top Venture Financing Deals in 2016 75

5 Pharmaceuticals & Healthcare, Global, Deal Summary, By Market 76

  • 5.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 76
    • 5.1.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, 2016 by Quarter 77
    • 5.1.2 Oncology - Deals of the Year 78
  • 5.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 82
    • 5.2.1 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, 2016 by Quarter 83
    • 5.2.2 Central Nervous System - Deals of the Year 84
  • 5.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 87
    • 5.3.1 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, 2016 by Quarter 89
    • 5.3.2 Infectious Disease - Deals of the Year 90
  • 5.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 92
    • 5.4.1 Pharmaceuticals & Healthcare, Global, Immunology Deals, 2016 by Quarter 94
    • 5.4.2 Immunology - Deals of the Year 95
  • 5.5 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 97
    • 5.5.1 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, 2016 by Quarter 98
    • 5.5.2 Cardiovascular - Deals of the Year 99
  • 5.6 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 101
    • 5.6.1 Pharmaceuticals & Healthcare, Global, Metabolic Disorders Deals, 2016 by Quarter 103
    • 5.6.2 Metabolic Disorders - Deals of the Year 104
  • 5.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 106
    • 5.7.1 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, 2016 by Quarter 108
    • 5.7.2 Gastrointestinal - Deals of the Year 109

6 Pharmaceuticals & Healthcare, Deal Summary, By Geography 112

  • 6.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 112
    • 6.1.1 Pharmaceuticals & Healthcare, North America Region, Deals, 2016 by Quarter 113
    • 6.1.2 North America - Deals of the Year 114
  • 6.2 Pharmaceuticals & Healthcare, European Region Deals, 2016 118
    • 6.2.1 Pharmaceuticals & Healthcare, Europe, Deals, 2016 by Quarter 119
    • 6.2.2 Europe - Deals of the Year 120
  • 6.3 Pharmaceuticals & Healthcare, Asia-Pacific Region, Deals, 2016 124
    • 6.3.1 Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, 2016 by Quarter 125
    • 6.3.2 Asia-Pacific - Deals of the Year 126
  • 6.4 Pharmaceuticals & Healthcare, Rest of the World (ROW) Deals, 2016 129
    • 6.4.1 Pharmaceuticals & Healthcare, Rest of the World Deals, 2016 by Quarter 130
    • 6.4.2 Rest of the World - Deals of the Year 131

7 Pharmaceuticals & Healthcare, Global, Top Financial Advisors 133

  • 7.1 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, M&A, 2016 133
  • 7.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, 2016 134

8 Further Information 136

  • 8.1 Methodology 136
  • 8.2 About GlobalData 137
  • 8.3 Contact Us 137
  • 8.4 Disclosure information 137
  • 8.5 Disclaimer 138

List of Tables

1.1 List of Tables

  • Table 1: Pharmaceutical & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 14
  • Table 2: Pharmaceuticals & Healthcare, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 15
  • Table 3: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Values (%), 2016 17
  • Table 4: Pharmaceuticals & Healthcare, Top Deals, Global, 2016 18
  • Table 5: Pharmaceuticals & Healthcare, Global, Top Deal Makers, Number of Deals and Deal Value (US$ m), 2016 24
  • Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 26
  • Table 7: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 27
  • Table 8: Pharmaceuticals & Healthcare, Global, Top M&A Deals, 2016 27
  • Table 9: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Values (US$ m), by Therapy Area, 2016 28
  • Table 10: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 29
  • Table 11: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 30
  • Table 12: Pharmaceuticals & Healthcare, Global, IPO Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 31

Table 13 Pharmaceuticals & Healthcare, Global, Top IPOs, 2016 32

  • Table 14: Pharmaceuticals & Healthcare, Global, Secondary Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 33
  • Table 15: Pharmaceuticals & Healthcare, Global, Top Secondary Offerings, 2016 33
  • Table 16: Pharmaceuticals & Healthcare, Global, PIPEs, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 34
  • Table 17: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, 2016 35
  • Table 18: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 36
  • Table 19: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 37
  • Table 20: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 38
  • Table 21: Pharmaceuticals & Healthcare, Global, Public Debt Offerings, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 39
  • Table 22: Pharmaceuticals & Healthcare, Global, Top Public Debt Offerings, 2016 39
  • Table 23: Pharmaceuticals & Healthcare, Global, Private Debt Placements, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 40
  • Table 24: Pharmaceuticals & Healthcare, Global, Top Private Debt Placements, 2016 41
  • Table 25: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), 2016 42
  • Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), 2012 - 2016 43
  • Table 27: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 44
  • Table 28: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 45
  • Table 29: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Values (US$ m), 2016 46
  • Table 30: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Values (US$ m), 2016 47
  • Table 31: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, 2016 49
  • Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Values (US$ m), 2016 51
  • Table 33: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2016 51
  • Table 34: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, 2016 52
  • Table 35: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, 2016 52
  • Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 53
  • Table 37: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 54
  • Table 38: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Number of Deals and Deal Values (US$ m), 2016 55
  • Table 39: Pharmaceuticals & Healthcare, Licensing Agreements, Upfront & Milestone Payments and Deal Values (US$ m), 2016 56
  • Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, Upfront & Milestone Payments and Deal Values (US$ m), 2016 57
  • Table 41: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q4 2015 - Q4 2016 60
  • Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Upfront & Milestone Payments and Deal Values (US$ m), 2016 62
  • Table 43: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Values (US$ m), 2016 62
  • Table 44: Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Upfront Payment, 2016 63
  • Table 45: Pharmaceutical & Healthcare, Global, Top Licensing Agreements, by Milestone Payment, 2016 63
  • Table 46: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 64
  • Table 47: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 65
  • Table 48: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, 2016 66
  • Table 49: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 67
  • Table 50: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 68
  • Table 51: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 69
  • Table 52: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), 2016 71
  • Table 53: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Number of Deals and Deal Values (US$ m), 2016 72
  • Table 54: Pharmaceutical & Healthcare, Global, Top VC Backed Companies, 2016 72
  • Table 55: Pharmaceuticals & Healthcare, Top Venture Financing Firms, Global, Number of Deals and Deal Value (US$ m), 2016 74
  • Table 56: Pharmaceuticals & Healthcare, Top Venture Financing Deals, Global, 2016 75
  • Table 57: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 77
  • Table 58: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 78
  • Table 59: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 83
  • Table 60: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 84
  • Table 61: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 88
  • Table 62: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 90
  • Table 63: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 93
  • Table 64: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 95
  • Table 65: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 98
  • Table 66: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 99
  • Table 67: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 102
  • Table 68: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 103
  • Table 69: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), 2012 - 2016 107
  • Table 70: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Values (US$ m), Q1 2016-Q4 2016 109
  • Table 71: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 113
  • Table 72: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 114
  • Table 73: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 119
  • Table 74: Pharmaceuticals & Healthcare, European Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 120
  • Table 75: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 125
  • Table 76: Pharmaceuticals & Healthcare, Asia-Pacific Region Deals, Deals Summary, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 126
  • Table 77: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), 2012 - 2016 130
  • Table 78: Pharmaceuticals & Healthcare, Rest of the World Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 131
  • Table 79: Pharmaceuticals & Healthcare, Global,, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), 2016 134
  • Table 80: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), 2016 135

List of Figures

1.2 List of Figures

  • Figure 1: Pharmaceutical & Healthcare, Global, Number of Deals and Deal Value (US$ m), 2012- 2016 13
  • Figure 2: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$ m), Q1 2016-Q4 2016 14
  • Figure 3: Pharmaceuticals &
Back to Top